Heart Disease Pregnancy

  • Uploaded by: khadzx
  • 0
  • 0
  • May 2020
  • PDF

This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA


Overview

Download & View Heart Disease Pregnancy as PDF for free.

More details

  • Words: 2,578
  • Pages: 50
Cardiac Diseases in Pregnancy • Dr.Uma Gupta MD,FICMCH • Dr.N.K.Gupta MS,MCh [email protected] [email protected] 08/01/09

Dr.Uma Dr.NK Gupta

1

The incidence and changing pattern of heart disease • It ranges from 0.1% to 4%. • Hospital statistics - industrialized countries have shown a decrease in the incidence from 0.9% to 0.3%

08/01/09

Dr.Uma Dr.NK Gupta

2

Incidence of heart disease……… Sharp decline in the incidence of chronic rheumatic heart disorders. Advances in the medical and surgical treatment of patients with congenital heart defects has resulted in an increased survival to reproductive age.

08/01/09

Dr.Uma Dr.NK Gupta

3

Maternal mortality from heart disease • Statistics have demonstrated a decline in maternal mortality from cardiac disease since 1950 from 5.6 to 0.3 per 100 000 births. • B’s of improved medical care of the pregnant cardiac patient and a sharp decrease in the incidence of rheumatic heart disease. 08/01/09

Dr.Uma Dr.NK Gupta

4

Maternal mortality from heart disease • Confidential enquiry of latest report on maternal deaths in the United Kingdom, has shown that cardiac disease accounted for the greatest number of maternal deaths • accounting for 35 (16.5%) of all maternal deaths over the period 1997–99* • (37 of 323) in the 1991 to 1993 triennium • (18) -1988 to 1990 trienniums • (23) -1985 to 1987 * de Swiet M. Cardiac disease. In: Lewis G, Drife J, eds. Why Mothers Die 1997–1999. The Confidential Enquiries into Maternal Deaths in the United

Kingdom. London: Royal College of Obstetricians and Gynaecologists, 2001; 153–64

08/01/09

Dr.Uma Dr.NK Gupta

5

Maternal mortality from heart disease Cardiac diseases is also the leading cause of indirect maternal death. Of the cardiac deaths reported to the Confidential enquiry between 20002002, 40% were noted to have substandard care. Deans CL, Uebing A, Steer PJ. Cardiac disease in pregnancy. In Progress in Obstetrics and Gynaecology, Vol 17, Edi Studd J, Tan S L, Chervenak FA.Churchill Livingstone 2007, 164-182. 08/01/09

Dr.Uma Dr.NK Gupta

6

Cardiovascular Physiology of Pregnancy • Normal pregnancy is associated with an increase of 30 to 50 percent in blood volume • Blood volume increases, starting at the sixth week and rising rapidly until mid pregnancy; the levels peak by 20 to 24 weeks of pregnancy and then are either sustained until term or decrease An estrogen-mediated stimulation of the reninangiotensin system results in sodium and water retention appears to be the mechanism underlying the blood volume increase. 08/01/09

Dr.Uma Dr.NK Gupta

7

Cardiovascular Physiology of Pregnancy • Increase in cardiac output is most significant change during pregnancy. • It begins to rise in first trimester and steadily rises to peak at 32 weeks by 30 to 50%. • Cardiac output is normally 4.2 L/min., is 6.5 L/min. at 8-10 weeks of pregnancy and remains so till near term. • Increase in cardiac output is achieved by rise in stroke volume (in early pregnancy) and Heart Rate (in latter part of pregnancy) adjusting together 08/01/09

Dr.Uma Dr.NK Gupta

8

Cardiovascular Physiology of Pregnancy • Due to rise in endogenous circulating catecholamine, there is positive inotropic and chronotropic myocardial response. • Later in pregnancy, the rise is related to an acceleration of heart rate (25%), since stroke volume decreases as a result of vena caval compression.

08/01/09

Dr.Uma Dr.NK Gupta

9

08/01/09

Dr.Uma Dr.NK Gupta

10

• Blood Pressure remains almost to prepregnant levels except a tendency to fall during pregnancy (particularly during midtrimester) as the systemic vascular/peripheral resistance falls (due to large arteriovenous shunts at placental bed and physiologic vasodilation secondary to endothelial prostacyclin and circulating progesterone) 08/01/09

Dr.Uma Dr.NK Gupta

11

• Colloid oncotic pressure is another important variable • Both plasma and interstitial colloid oncotic pressure decrease throughout pregnancy • There is accompanying increase in capillary hydrostatic pressure. • An increase in hydrostatic pressure or a decrease in colloid oncotic pressure may overcome the delicate balance that favors oedema formation 08/01/09

Dr.Uma Dr.NK Gupta

12

Colloid oncotic pressure • After delivery, decrease in plasma colloid oncotic pressure takes place reaching a peak between 6 to 16 hours and returns towards intrapartum level after 24 hours. • These changes can lead to dependant oedema complicating diagnosis of cardiac decompensation.

08/01/09

Dr.Uma Dr.NK Gupta

13

Simulating cardiac disease Owing to these normal changes, many healthy pregnant women have symptoms mimicking those of cardiac disease, Including: fatigue, dyspnea, and light-headedness, & number of “abnormal” findings on physical examination, electrocardiography, and echocardiography 08/01/09

Dr.Uma Dr.NK Gupta

14

08/01/09

Table 1. Normal physiological changes of pregnancy that mimic symptoms and signs of cardiac disease Symptoms Tiredness Dyspnoea Orthopnoea Syncope Light-headedness Physical signs Peripheral oedema Hyperventilation Distended neck veins with prominent A and V waves Brisk, diffuse, and displaced left ventricular impulse Palpable right ventricular impulse Increased S1 intensity Persistent splitting of S2 Early ejection systolic murmurs at lower left sternal edge or pulmonary area Cervical venous Dr.Umahum Dr.NK Gupta 15 Mammary souffle

Contd.. Table 1. Normal physiological changes of pregnancy that mimic symptoms and signs of cardiac disease

08/01/09

Electrocardiogram Left axis deviation ST segment and T wave changes Small Q, inverted P or T wave in lead III Increased R wave amplitude in lead V2 Atrial or ventricular ectopics Chest X-ray Straightened left upper cardiac border Horizontal heart position Increased lung markings Echocardiogram Increased left/right ventricular dimensions Mild increase in left/right atrial size Slightly improved left ventricular systolic function Functional tricuspid/pulmonary insufficiency Small pericardial Dr.Uma effusion Dr.NK Gupta

16

Management areas Areas be considered in the clinical approach to the woman with heart disease who is pregnant or considering pregnancy: 2) Risk stratification, Pre-conceptional 3) Antepartum management, 4) Peripartum management, 4) Recurrence of congenital lesion in the neonate, 5) Site of antepartum and peripartum care.

08/01/09

Dr.Uma Dr.NK Gupta

17

Pre-conceptional counselling • This is an important aspect of management or the cardiac patient planning a pregnancy. • Ideally, the obstetrician and cardiologist should work together to help the patient make an informed decision. • Prevent an unwanted pregnancy and avoid the risks associated with pregnancy continuation or termination. 08/01/09

Dr.Uma Dr.NK Gupta

18

Risk assessment • Poor functional status (NYHA class III or IV) or cyanosis • Left ventricular systolic dysfunction (ejection fraction < 0.40) • Left heart obstruction (mitral valve area <2.0 cm2, aortic valve area < 1.5 cm2, or peak left ventricular outflow tract gradient > 30 mm Hg) 08/01/09

Dr.Uma Dr.NK Gupta

19

Risk assessment A cardiac event (arrhythmia, stroke, transient ischemic attack, or pulmonary edema) before pregnancy but since a prior cardiac surgical procedure.

08/01/09

Dr.Uma Dr.NK Gupta

20

Risk assessment Siu developed a risk index incorporating these factors. In a woman with heart disease and no other risk factors, the likelihood of a cardiac event during pregnancy is about 5%, increasing to 25% with one risk factor & 75% with more than one risk factor. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515–521.

08/01/09

Dr.Uma Dr.NK Gupta

21

Table 2. Maternal mortality risk and cardiac disease Group Cardiac disease Associated mortality risk I Atrial septal defect* <1% Ventricular septal defect* Patent ductus arteriosus* Pulmonary/tricuspid valve disease Corrected tetralogy of Fallot Bioprosthetic valve Mitral stenosis, NYHA Class I, II II Coarctation of aorta without valvular involvement 5% - 15% Uncorrected tetralogy of Fallot Marfan’s syndrome with normal aorta Mechanical prosthetic valve Mitral stenosis with atrial fibrillation or NYHA Class III, IV Aortic stenosis Previous myocardial infarction III Pulmonary hypertension—primary or secondary 25% - 50% Coarctation of aorta with valvular involvement Marfan’s syndrome with aortic involvement Peripartum cardiomyopathy *Uncomplicated

08/01/09

Dr.Uma Dr.NK Gupta

22

• A careful history is obtained to identify previous cardiac complications. • The patients functional status as per The New York Heart Association(NYHA) is defined

08/01/09

Dr.Uma Dr.NK Gupta

23

Table 3.NEW YORK HEART ASSOCIATION FUNCTIONAL CLASSIFICATION OF CARDIAC DISEASE CLASS I

No functional limitation of activity. No symptoms of cardiac decompensation with activity.

CLASS II

Mild amount of functional limitation. Patients are asymptomatic at rest. Ordinary physical activity results in symptoms.

CLASS III

Limitation of most physical activity. Asymptomatic at rest Minimal physical activity results in symptoms.

CLASS IV

Severe limitation of physical activity results in symptoms. Patients may be symptomatic at rest/heart failure at any point of pregnancy.

CLASS V

If patient is on ionotropic support, ventilator, Assisted circulation or having comprised renal or pulmonary function necessitating dialysis/EMCO to maintain vital signs.

The criteria committee of the New York Heart Association, Nomenclature and criteria for diagnosis of diseases of heart and great vessels, Edi 8, New York Association,1979.

08/01/09

Dr.Uma Dr.NK Gupta

24

Antepartum Care • The chief aim of management of the patient in pregnancy is to keep patient within her cardiac reserve. • It is preferable to have detailed baseline information prior of pregnancy.

08/01/09

Dr.Uma Dr.NK Gupta

25

Antepartum care • Limiting activity is helpful in severely affected women with ventricular dysfunction, • left heart obstruction, or class III or IV symptoms. • Hospital admission by mid-second trimester may be advisable for some. 08/01/09

Dr.Uma Dr.NK Gupta

26

Antepartum care • Problems should be identified early and treated aggressively, especially pregnancy induced hypertension, hyperthyroidism, infection, and anemia.

08/01/09

Dr.Uma Dr.NK Gupta

27

Table 4. Recommended antibiotic prophylaxis for high-risk women undergoing genitourinary or gastrointestinal procedures Category

Drug and dosage

High-risk patient

Ampicillin, 2 g IM or IV, plus gentamicin sulfate (Garamycin), 1.5 mg/kg IV 30 min before procedure; ampicillin, 1 g IV, or amoxicillin (Amoxil, Trimox, Wymox), 1 g PO 6 hr after procedure

High-risk patient who has penicillin allergy

Vancomycin HCl (Vancocin, Vancoled), 1 g IV over 2 hr, plus gentamicin sulfate, 1.5 mg/kg IV 30 min before procedure

08/01/09

Dr.Uma Dr.NK Gupta

28

08/01/09

Dr.Uma Dr.NK Gupta

29

Antepartum care Beta-blockers rather than digoxin should be used to control the heart rate for patients with functionally significant mitral stenosis. Empiric therapy with beta-blockers is offered to patients with coarctation, Marfan syndrome, and ascending aortopathy for other reasons (eg, a bicuspid aortic valve).

08/01/09

Dr.Uma Dr.NK Gupta

30

Arrhythmias should be treated if warranted Premature atrial or ventricular beats are common in normal pregnancy, and in patients with preexisting arrhythmias, Pregnancy may exacerbate their frequency and hemodynamic severity. These usually are not treated.

08/01/09

Dr.Uma Dr.NK Gupta

31

Antepartum care Sustained tachyarrhythmias, such as atrial flutter or atrial fibrillation, should be treated promptly. If possible, all antiarrhythmic drugs should be avoided during the first trimester, and those known to be teratogenic should be avoided throughout pregnancy. Because of their safety profiles, preferred drugs include digoxin, beta-blockers and adenosine. 08/01/09

Dr.Uma Dr.NK Gupta

32

08/01/09

Dr.Uma Dr.NK Gupta

33

Antepartum care • Anticoagulation therapy. No current strategy is equally safe for both mother and fetus.

08/01/09

Dr.Uma Dr.NK Gupta

34

Anticoagulation therapy Oral therapy with warfarin is effective and logistically easy. However, it can affect embryonic organ development, although some evidence shows that a dosage of 5 mg per day may not be teratogenic. Fetal intracranial bleeding is a risk throughout pregnancy, particularly during vaginal delivery, unless warfarin is stopped before labor. 08/01/09

Dr.Uma Dr.NK Gupta

35

Anticoagulation therapy * Heparin in adjusted subcutaneous doses does not cross the placenta and so has no teratogenic effects. However, it may cause maternal thrombocytopenia and osteoporosis and is less effective in preventing thrombosis in patients with prosthetic valves. 08/01/09

Dr.Uma Dr.NK Gupta

36

Anticoagulation therapy More recent guidelines recommend either (1) adjusted-dose heparin during the entire pregnancy or (2) adjusted-dose heparin until the 13th week of gestation, warfarin from the 14th week to the middle of the third trimester, and then restart adjusted-dose heparin. * Low-molecular-weight heparin in adjusted doses is easier to administer and has been suggested as an alternative to adjusted-dose unfractionated heparin. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy. Chest 2004; 126:627S– 644S 08/01/09

.

Dr.Uma Dr.NK Gupta

37

Anticoagulation therapy At week 36 # *Discontinue warfarin *Change to UFH titrated to a therapeutic aPTT or antifactor Xa level. At Delivery: *Restart heparin therapy 4 to 6 hr after delivery if no contraindications *Resume warfarin therapy the night after delivery if no bleeding complications #if labor begins while the woman is receiving warfarin, anticoagulation should be reversed and caesarean delivery performed Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:Suppl:122S-131S

08/01/09

Dr.Uma Dr.NK Gupta

38

Anticoagulation therapy Monitoring • With LMWH administered sc. twice daily maintain anti-Xa level between 0.7 and 1.2 U/ml 4 hours after admn. • With dose adjusted UFH, the aPTT should be at least twice control. • those on warfarin, the INR goal should be 3.0(range 2.5 to 3.5) Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-196

08/01/09

Dr.Uma Dr.NK Gupta

39

Peripartum management • Cesarean section is indicated only for the following conditions: • Aortic dissection • Marfan syndrome with dilated aortic root • Taking warfarin within 2 weeks of labor.

08/01/09

Dr.Uma Dr.NK Gupta

40

Peripartum care Preterm induction is uncommon. However, once fetal lung maturity is assured, a planned induction and delivery may be warranted for high-risk patients to ensure that appropriate staff and equipment are available.

08/01/09

Dr.Uma Dr.NK Gupta

41

Peripartum care Antibiotic prophylaxis for endocarditis is not routine. AHA guidelines do not recommend routine endocarditis prophylaxis for cesarean section delivery or for uncomplicated vaginal delivery without infection.37 However, some centers do administer endocarditis prophylaxis for vaginal delivery in women with structural heart disease, as an uncomplicated delivery cannot always be anticipated. 08/01/09

Dr.Uma Dr.NK Gupta

42

Peripartum care Positioning the patient on her left side lessens the hemodynamic fluctuations associated with contractions when the patient is supine.

08/01/09

Dr.Uma Dr.NK Gupta

43

Peripartum care • Forceps or vacuum extraction should be considered at the end of the second stage of labor to shorten and ease delivery.

08/01/09

Dr.Uma Dr.NK Gupta

44

Peripartum care • Postpartum monitoring Because hemodynamics do not return to baseline for many days after delivery, patients at intermediate or high risk may require monitoring for at least 72 hours postpartum.

08/01/09

Dr.Uma Dr.NK Gupta

45

Peripartum care • Lactation should be encouraged unless patient is in failure. • Cardiac output is not compromised during lactation. • Lactation is a pathway for fluid excretion and diuretic requirement may actually fall.

08/01/09

Dr.Uma Dr.NK Gupta

46

Contraception • Barrier methods – unreliable. • COC contraindicated. • Progesterone only pill have better side effect profile & long acting slow releasing as Mirena intrauterine system have improved efficacy. • Sterilization where family completed. (Laparoscopic clip sterilization carries risk). Deans CL, Uebing A, Steer PJ. Cardiac disease in pregnancy. In Progress

in Obstetrics and Gynaecology, Vol 17, Edi Studd J, Tan S L,

Chervenak FA.Churchill Livingstone 2007, 164-182.

08/01/09

Dr.Uma Dr.NK Gupta

47

Conclusion Pregnancy causes significant haemodynamic changes and imposes an additional burden on the cardiac patient, especially around the time of labour and in the immediate puerperium. To achieve a successful pregnancy outcome, a clear understanding of these haemodynamic adaptations as well as meticulous maternal and foetal surveillance for risk factors and complications throughout the pregnancy is essential. 08/01/09

Dr.Uma Dr.NK Gupta

48

Conclusion Appropriate contraceptive and family planning advice as well as pre-conceptional counselling are also important. The concerted efforts of a team consisting of the obstetrician, cardiologist, anaesthetist, cardiothoracic surgeon, neonatologist, and paediatric cardiologist are mandatory to ensure optimal results.

08/01/09

Dr.Uma Dr.NK Gupta

49

08/01/09

Dr.Uma Dr.NK Gupta

50

Related Documents

Heart Disease
June 2020 17
Cardiac Disease In Pregnancy
November 2019 26
Abc Of Heart Disease
December 2019 25
Acquired Heart Disease
December 2019 15

More Documents from ""